These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2127895)

  • 1. Hypertension following erythropoietin therapy in anemic hemodialysis patients.
    Buckner FS; Eschbach JW; Haley NR; Davidson RC; Adamson JW
    Am J Hypertens; 1990 Dec; 3(12 Pt 1):947-55. PubMed ID: 2127895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
    Walter J; Gål J; Taraba I
    Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
    Campos A; Garin EH
    Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension as a possible complication of recombinant human erythropoietin therapy.
    Brunkhorst R; Nonnast-Daniel B; Koch KM; Frei U
    Contrib Nephrol; 1991; 88():118-25; discussion 126. PubMed ID: 2040173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin associated hypertension among pediatric dialysis patients.
    Komatsu Y; Ito K
    Adv Perit Dial; 1992; 8():448-52. PubMed ID: 1361845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
    Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
    Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
    Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
    Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of erythropoietin on blood pressure.
    Raine AE; Roger SD
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):76-83. PubMed ID: 1928084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The haemodynamic effects of correction of anaemia in haemodialysis patients using recombinant human erythropoietin.
    Abdulhadi MH; Fouad-Tarazi FM; Thomas T; Bravo EL; Paganini EP
    Nephrol Dial Transplant; 1990; 5 Suppl 1():102-8. PubMed ID: 2129437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin.
    Nonnast-Daniel B; Schäffer J; Frei U
    Contrib Nephrol; 1989; 76():283-9; discussion 290-1. PubMed ID: 2684528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy.
    Kaupke CJ; Kim S; Vaziri ND
    J Am Soc Nephrol; 1994 May; 4(11):1874-8. PubMed ID: 7919137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin.
    Kamata K; Marumo F; Onoyama K
    Jpn Circ J; 1991 Jul; 55(7):649-56. PubMed ID: 1880896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Erythropoietin--the first hematologic hormone in clinical use].
    Rhyner K
    Schweiz Med Wochenschr; 1988 Mar; 118(11):375-80. PubMed ID: 3287601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disordered alpha 2-adrenoreceptor function in hemodialysis patients with renal anemia--a possible cause of increased blood pressure in relation to recombinant human erythropoietin?].
    Müller R; Steffen HM; Brunner R; Pollok M; Baldamus CA; Kaufmann W
    Klin Wochenschr; 1991 Oct; 69(16):742-8. PubMed ID: 1662322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
    Brown CD; Friedman EA
    Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin.
    Schaefer RM; Leschke M; Strauer BE; Heidland A
    Am J Nephrol; 1988; 8(6):449-53. PubMed ID: 3218658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.